Skip to content
Therapy But Better – Lifestyle
Author:
Lupin Pharmaceuticals, Inc.
Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States
November 3, 2026
Lupin Receives U.S. FDA Approval for Amifampridine Tablets
November 2, 2026
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP
October 8, 2026
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
September 28, 2026
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
September 4, 2026
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
August 17, 2026
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
August 10, 2026
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
July 30, 2026
Lupin Announces the Approval of Diazepam Injection, USP in the United States
July 28, 2026
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
July 21, 2026
1
2
Next Page
→